publication date: Jun. 30, 2017

BSA, NCAB approve nine Cancer Moonshot concepts based on Blue Ribbon Panel recommendations

By Matthew Bin Han Ong

The NCI Board of Scientific Advisors and the National Cancer Advisory Board unanimously approved nine Cancer Moonshot-related funding opportunity announcements.

The approvals bring the total number of NCI Cancer Moonshot FOAs to 33, of which 11 have been closed. The FOAs are aligned with the NCI Blue Ribbon Panel scientific recommendations, which were presented to the White House less than a year ago.

“The good news is there was a lot of interest. We’ve gotten over 500 applications across the board,” Dinah Singer, director of NCI Division of Cancer Biology, said at the BSA-NCAB June 20-21 joint meeting. “Within FY2017, we will have already launched a number of initiatives that are aimed at accomplishing the goals that were laid out in the recommendations of the Blue Ribbon Panel.”

All the RFAs, which are managed by the moonshot implementation teams, will include language requiring the consideration of health disparities, if applicable, and a requirement for open access.

The nine FOAs approved by the BSA and NCAB follow:

The review of Common Terminology Criteria for Adverse Event reporting system aims to identify gaps in analyzing adverse event data and assess tolerability of anti-cancer agents using clinician- and patient-reported outcomes.

Submitted by the Blue Ribbon Panel Symptom Management Implementation Team, the Request for Applications would include patient reporting of adverse events and other clinically relevant data to stimulate development of methods for analyzing AE data and to determine drug tolerability.

The RFA, which as unanimously approved with modifications, stems from the panel’s recommendation to “identify approaches to monitor and manage … Continue reading BSA, NCAB approve nine Cancer Moonshot concepts based on Blue Ribbon Panel recommendations

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.